Skip to content

Welcome to Discover Pharma! Today is : October 27, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

bispecific antibody

  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer

    Context Therapeutics has reported encouraging interim Phase 1 data for [...]

    June 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg begins patient recruitment for POLB 001 TOPICAL trial

    Poolbeg Pharma has activated the first clinical site and begun [...]

    June 11, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    SMC approves TALVEY for relapsed multiple myeloma in Scotland

    The Scottish Medicines Consortium (SMC) has accepted TALVEY (talquetamab) for [...]

    June 9, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Mestag Therapeutics doses first patient in Phase 1 STARLYS solid tumour trial

    Mestag Therapeutics has dosed the first patient in its Phase [...]

    May 28, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Manufacturing & Supply Chain,Therapeutic Areas

    Mestag Therapeutics raises $40M and adds leadership ahead of cancer trial

    Mestag Therapeutics has raised $40 million and appointed two senior [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Talquetamab recommended by NICE for relapsed and refractory multiple myeloma

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory

    Alys Pharmaceuticals submits CTA for mast cell-selective c-Kit inhibitor in cold urticaria

    Alys Pharmaceuticals has submitted a clinical trial application (CTA) in [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Johnson & Johnson reports three-year Crohn’s disease results for guselkumab
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Ryvu reports preclinical results for novel ADC payload
    Categories: Drug Discovery & Development, Research & Development
  • Kindeva wins $226 million contract for nerve agent antidote autoinjectors
    Categories: Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top